Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (819)	1/23/2000 1:30:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

Mike... I very much like the superantigen program, but... potent adjuvancy, but same old issue..... delivery and adjuvant for what? Looking at it, with intent of looking closely. No time (or incorrect allocation of time, take your choice). Larry..... a don't like the representations of potential for the IL-1 antagonist(s). Not a viable project, and they know it. Gives a clear picture of management's style, IMO. Seems like a good list, otherwise.